Riluzole in augmentation of fluvoxamine for moderate to severe obsessive–compulsive disorder: Randomized, double‐blind, placebo‐controlled study
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Aim: The aim of the present randomized, double‐blind, placebo‐controlled, 8‐week trial was to assess the efficacy and tolerability of riluzole augmentation of fluvoxamine in treatment of patients with moderate to severe obsessive–compulsive disorder. Methods: Patients were randomized into two parallel groups to receive fluvoxamine plus placebo or fluvoxamine plus riluzole (50 mg twice daily). All patients, regardless of their treatment group, received fluvoxamine at 100 mg/day for the initial 4 weeks of the study followed by 200 mg/day of fluvoxamine for the rest of the trial course. A total of 50 patients (25 in each group) were evaluated for response to treatment using the Yale–B rown O bsessive C ompulsive S cale (Y‐BOCS) at baseline and at weeks 4, 8 and 10. Side‐effects were recorded using predesigned checklists in each visit. Repeated‐measure analysis of variance showed a significant effect for time × treatment interaction in the Y‐BOCS total score and a significant effect for time × treatment interaction in the Y‐BOCS Compulsive subscale score between the two groups. Results: Repeated‐measure analysis of variance showed a significant effect for time × treatment interaction (Greenhouse–G eisser corrected: F = 4.07, d.f. = 1.22, P = 0.04) in the Y‐BOCS total score and a significant effect for time × treatment interaction (Greenhouse–G eisser corrected: F = 4.45, d.f. = 1.33, P = 0.028) in the Y‐BOCS Compulsive subscale score between the two groups. Riluzole augmentation therapy demonstrated higher, partial or complete treatment response according to the Y‐BOCS total scores. Conclusion: Riluzole may be of clinical use as an adjuvant agent to fluvoxamine in treatment of moderate to severe obsessive–compulsive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001823 · Cited by 635
Grant, J. E., Odlaug, B. L., & Won Kim, S. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.60 · Cited by 424 · cited 1×
“Another 12-week open-label trial of riluzole on six treatment-resistant children with OCD showed that four had >46% reduction in the Children’s Yale– Brown Obsessive–Compulsive Scale severity scores.(48) The authors noted that the side-effect profile was benign and that all patients elected to remain on riluzole post-…”
BackgroundPallanti, S., & Quercioli, L. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.028 · Cited by 408
ROSENBERG, D. R., MacMASTER, F. P., KESHAVAN, M. S., FITZGERALD, K. D., STEWART, C. M., & MOORE, G. J. (2000) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200009000-00008 · Cited by 377
Glutamatergic Dysfunction in OCD
Chakrabarty, K., Bhattacharyya, S., Christopher, R., & Khanna, S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300733 · Cited by 344 · cited 1×
“Studies on the cerebrospinal fluid of patients with OCD have also shown significantly higher glutamate concentrations in patients compared to controls.(17,18) Neuropharmacology research on glutamate-modulating drugs has provided evidence in support of developing new agents targeting this pathway and their use in the m…”
ResultSoomro, G. M., Altman, D. G., Rajagopal, S., & Oakley Browne, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001765.pub3 · Cited by 342 · cited 9×
“Impairment in both direct and indirect loops of this circuit has been previously reported.40 Moreover, proton magnetic resonance spectroscopy (1H-MRS) studies have shown dysregulation in glutamate resonance in the caudate nucleus,41 and the anterior cingulate cortex.16 Taken together in conjunction with evidence for i…”
BackgroundInfluentialRiluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314 · cited 11×
“Previous studies evaluating the efficacy of riluzole on OCD symptoms were used as guides for riluzole dosage.(30,34) All patients, regardless of their treatment group, received fluvoxamine at 100 mg/day for the initial 4 weeks of the study followed by 200 mg/day for the rest of the trial course.”
BackgroundMethodResultInfluentialThe role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264 · cited 1×
“In this regard, dysregulation of the cortico-striatal-thalamo-cortical circuitry is a key component in OCD pathophysiology.(14) Disruption of glutamatergic transmission, the main excitatory transmitter of this circuitry, has been reported in several studies on patients with OCD.”
ResultROSENBERG, D. R., MIRZA, Y., RUSSELL, A., TANG, J., SMITH, J. M., BANERJEE, S. P., BHANDARI, R., ROSE, M., IVEY, J., BOYD, C., et al. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000132812.44664.2d · Cited by 246
Cited by
Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt, M. E., Bloch, M. H., & Mathews, C. A. (2017) · JAMA · doi:10.1001/jama.2017.2200 · Cited by 493
Fineberg, N. A., Hollander, E., Pallanti, S., Walitza, S., Grünblatt, E., Dell’Osso, B. M., Albert, U., Geller, D. A., Brakoulias, V., Janardhan Reddy, Y. C., et al. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000314 · Cited by 161
Albert, U., Marazziti, D., Di Salvo, G., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666171222163645 · Cited by 90
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
“Finally, in a double-blind, placebo-controlled trial of 50 adult OCD patients adjunctive therapy with riluzole in addition to fluvoxamine treatment for 10 weeks resulted in greater reduction of total and compulsions subscale Y-BOCS scores compared to the fluvoxamine group [75].”
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Metadata
- Authors
- Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S.
- Venue
- Psychiatry and Clinical Neurosciences
- Publisher
- Wiley
- Published
- 2016-05-26
- Volume
- 70
- Issue
- 8
- Pages
- 332-341
- ISSN
- 1323-1316 (ISSN-L)
- 1440-1819
- OpenAlex
- W2341125861
- Cited by
- 55
- References
- 21
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Riluzole in augmentation of fluvoxamine for moderate to severe obsessive–compulsive disorder: Randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/pcn.12394
- The paper
- Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016). Riluzole in augmentation of fluvoxamine for moderate to severe obsessive–compulsive disorder: Randomized, double‐blind, placebo‐controlled study. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12394
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.